OLYMPIA, Wash., March 3, 2026 /PRNewswire/ — A recently published Phase I/II clinical trial in the peer-reviewed journal BMC Immunology, and announced by University of California San Diego (UCSD), evaluated a combination of Fomitopsis officinalis (Agarikon) and Trametes versicolor…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
